Recent Updates — CTXR

Citius Pharmaceuticals reported preliminary, unaudited data showing a 120% increase in LYMPHIR unit sales to U.S. wholesalers during the fiscal fourth quarter ended September 30, 2026, rising from 360 units in the prior quarter to 792 units. Prescribing centers ordered 950 vials during the period, and the number of institutions ordering the drug increased to 54 from 44 as of mid-August. The company attributes this growth to expanded commercial coverage achieved in August and expects momentum to continue into fiscal 2027. Citius Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing critical care products.

On August 17, 2026, Citius Pharmaceuticals received notice from Nasdaq granting an extension until February 8, 2027, to demonstrate compliance with the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2). The company must maintain a closing bid price of at least $1.00 for ten consecutive business days before that date to avoid delisting proceedings. Failure to regain compliance by February 8, 2027, will result in written notice of potential delisting, though the stock continues to trade under the symbol CTXR on the Nasdaq Capital Market while options are evaluated. Citius Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of pharmaceutical products.